Phosphorothioate-Modified AP613-1 Specifically Targets GPC3 when Used for Hepatocellular Carcinoma Cell Imaging
Glypican-3 (GPC3), the cellular membrane proteoglycan, has been established as a tumor biomarker for early diagnosis of hepatocellular carcinoma (HCC). GPC3 is highly expressed in more than 70% HCC tissues detected by antibody-based histopathological systems. Recently, aptamers, a short single-stran...
Main Authors: | Lili Dong, Hongxin Zhou, Menglong Zhao, Xinghui Gao, Yang Liu, Dongli Liu, Wei Guo, Hongwei Hu, Qian Xie, Jia Fan, Jiang Lin, Weizhong Wu |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2018-12-01
|
Series: | Molecular Therapy: Nucleic Acids |
Online Access: | http://www.sciencedirect.com/science/article/pii/S2162253118302579 |
Similar Items
-
GPC-3 in hepatocellular carcinoma: current perspectives
by: Wu Y, et al.
Published: (2016-11-01) -
Anti-GPC3 antibody-modified sorafenib-loaded nanoparticles significantly inhibited HepG2 hepatocellular carcinoma
by: Xiaolong Tang, et al.
Published: (2018-01-01) -
Critical analysis of the potential of targeting GPC3 in hepatocellular carcinoma
by: Ofuji K, et al.
Published: (2014-05-01) -
Studies in the synthesis of phosphorothioate analogues of oligonucleotides
by: Liu, Xiaohai
Published: (1996) -
Preparation and Characterization of Anti-GPC3 Nanobody Against Hepatocellular Carcinoma
by: Xia L, et al.
Published: (2020-03-01)